Business UpdateMay 26, 2026, 07:32 AM
Plus Therapeutics' CNSide Reduces LM Healthcare Costs by 40%
AI Summary
Plus Therapeutics announced a health economics study, co-authored with Harvard, demonstrating that its CNSide cerebrospinal fluid assay can reduce overall leptomeningeal metastases (LM)-related healthcare costs by approximately 33-47%, averaging 40%. This reduction is attributed to earlier therapeutic intervention, improved treatment precision, and fewer hospitalizations. The findings, presented at the ISPOR 2026 Annual Meeting and receiving blue-ribbon recognition, validate CNSide's value for payers and support its commercialization in the US.
Key Highlights
- CNSide assay may reduce overall LM-related healthcare costs by ~40% (33-47%).
- Potential savings are driven by earlier therapeutic intervention and reduced hospitalizations.
- Late-stage LM diagnosis is associated with median inpatient admissions of ~$20,000.
- Total LM-related costs may exceed $100,000 per month.
- The presentation received Blue Ribbon recognition, awarded to the top 5% at ISPOR.
- Leptomeningeal metastases (LM) affect ~5% of patients with metastatic cancer.
- Median survival for LM patients is typically 2-6 months.
Price Impact
More from PSTV